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EFFECTIVENESS OF ROPIVACAINE BLOCKS IN ELECTIVE 
OVARIOHYSTERECTOMY IN DOGS FOR CONTROL OF POST-OPERATIVE PAIN 
Abstract 
Nowadays, pain is an ever-present theme in veterinary practice. The number of available tools 
to fight painful stimuli has increased and practicians are more accurate in recognizing pain in 
their patients. However, much is still to be discovered and full drug potential hasn’t yet been 
achieved.  
The present study was meant to test the efficacy of the use of  ropivacaine as a mean to 
control post-operative pain, by subcutaneous administration over the incision line, in elective 
ovariohysterectomies in female dogs. Glasgow’s Composite Measure Pain Scale was used as 
pain assessment tool. Pain assessment began thirty minutes post-extubation and was repeated 
hourly, up until 6 hours post-local block (limit of ropivacaine’s action).   
In this study, 14 dogs were received at the Veterinary Teaching Hospital of the Veterinary 
Medicine Faculty of the University of Lisbon (HEFMV-ULisbon) for elective 
ovariohysterectomy. They were randomly distributed into two groups – Ropivacaine Group 
(RG) and Saline Group (SG). The observer was blinded to the distribution during the study 
period. RG was submitted to a subcutaneous infiltration of 1 mg/kg of ropivacaine, while SG 
patients were subject to a saline infiltration – volume calculation as per ropivacaine’s dose 
and concentration. During the procedure, heart and respiratory rate were monitored, with 
special attention to 5 crucial time-points. Post-operatively, rescue analgesia (carprofen 4 
mg/kg + buprenorphine 0,015 mg/kg) were given to either patients whose score was 5 or 
greater in pain assessment or after 6 hours had passed, whichever came first. After the 
administration of rescue analgesia, the study was ended for that patient. Statistical analysis 
was done with R v2.1.2.  
There were no statistical differences between groups in age, weight, duration of procedure and 
duration of anesthesia (p = 0.743, p = 0.318, p = 0.796 and p = 0.337, respectively). 
Comparison between groups wasn’t statistically significant in heart and respiratory rate in the 
5 chosen time-points (p = 0.990 e p = 0.529, respectively) nor in pain scores (p = 0.638).  
In conclusion, anesthesia with methadone, acepromazine, propofol and isoflurane provided 
reliable analgesia during and after the procedure, since no supplemental analgesics were 
needed in the control group. The pre-incisional administration of 1 mg/kg SC ropivacaine did 
not prove effective in lowering post-op pain scores. 
Keywords: Analgesia, local anesthetic, pain evaluation, ropivacaine, dog, 
ovariohysterectomy  
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EFICÁCIA DE BLOQUEIOS ANESTÉSICOS COM ROPIVACAÍNA EM 
OVARIOHISTERECTOMIAS ELECTIVAS EM CADELAS PARA CONTROLO DA DOR 
PÓS-OPERATÓRIA 
Resumo 
A temática da dor está, hoje em dia, sempre presente na prática veterinária. As ferramentas de 
combate aos estímulos álgicos têm aumentado e os veterinários estão mais eficazes a 
reconhecer estados de dor nos seus pacientes. No entanto, ainda muito está por descobrir e 
ainda é possível aumentar a potencialidade de alguns fármacos disponíveis para o efeito.  
O presente estudo teve como objectivo averiguar a eficácia da utilização de ropivacaína como 
meio de controlo de dor pós-cirúrgica, através da sua infiltração subcutânea na linha de 
incisão em ovariohisterectomias electivas de cadelas. Para efeitos de avaliação de dor pós-
cirúrgica, foi usada a Escala Composta Multidimensional de Avaliação de Dor da 
Universidade de Glasgow, com início da avaliação trinta minutos após a extubação e 
novamente de hora a hora, sendo a última avaliação quando se completaram as seis horas pós-
infiltração (tempo de acção da ropivacaína).  
Neste estudo participaram 14 animais que compareceram no Hospital Escolar da Faculdade de 
Medicina Veterinária da Universidade de Lisboa (HEFMV-ULisboa), que foram 
posteriormente aleatóriamente colocados em dois grupos – Grupo Ropivacaína (GR) e grupo 
Salino (GS). O observador não teve conhecimento do grupo a que cada paciente pertencia 
durante o decorrer do estudo. O GR foi sujeito a uma infiltração subcutânea de 1 mg/kg de 
ropivacaína, enquanto que o GS foi sujeito ao mesmo procedimento com soro salino, sendo o 
volume calculado tendo em conta a dose e a concentração da ropivacaína. Durante o 
procedimento foram monitorizados a frequência cardíaca e a frequência respiratória, tendo 
destaque 5 momentos temporais cruciais do procedimento. No pós-cirúrgico, a analgesia de 
resgate (carprofeno 4 mg/kg + buprenorfina 0,015 mg/kg) foi administrada a pacientes que 
apresentassem um score de 5 ou mais durante as monitorizações ou após finalizadas as 6 
horas pós-infiltração. Após esta administração, o estudo deu-se por terminado para o paciente 
em questão. A análise estatística foi realizada com base no software R v3.1.2. 
Neste estudo, não houve diferenças significativas entre grupos para idade, peso, duração do 
procedimento e duração da anestesia (p = 0.743, p = 0.318, p = 0.796 e p = 0.337, 
respectivamente). A comparação entre grupos em termos de frequência cardíaca e respiratória 
dos pacientes nos 5 momentos escolhidos (p = 0.990 e p = 0.529, respectivamente) e de 
scores de dor (p = 0.638) não foi estatisticamente significante.  
Conclui-se então que o protocolo anestésico foi apropriado para o procedimento, uma vez que 
não foi necessária analgesia suplementar para nenhum paciente do grupo de controlo. 
Conclui-se também que a administração SC pré-incisional de 1 mg/kg de ropivacaína não 
contribui para uma redução dos scores de dor dos pacientes após OVH. 
Palavras-chave: Analgesia, anestésico local, avaliação de dor, cão, ovariohisterectomia, 
ropivacaína 
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Part I - Bibliographic review 
1.  Pain and its definitions 
Pain is the single, hardest emotion to describe. It is usually classified as an unpleasant feeling, 
often related to tissue lesion. There have been numerous attempts of defining it, though many 
of them aren’t explicit enough to fully describe what pain is. The official definition of pain by 
the International Association for the Study of Pain (IASP) is “an unpleasant sensory and 
emotional experience, associated with actual or potential tissue damage, or described in terms 
of such damage”. 
Molony has also defined pain in a most interesting way, taking into account animal pain: “An 
aversive sensory and emotional experience representing awareness by the animal of damage 
or threat to the integrity of tissues. It changes the animal’s physiology and behavior to reduce 
or avoid the damage, to reduce the likelihood of recurrence and to promote recovery.” 
(Molony & Kent, 1997)  
Both definitions equally state that pain isn’t just a physical phenomena (the lesion per se), but 
it also has psychological, behavioral and cognitive elements as well (the latter only in the 
species with important cortical development – i.e. primates). As an example of the interaction 
between those elements, the limbic system (a system responsible for some emotions, like fear 
and anxiety) gives feedback to the cortex, which means that fear and anxiety (psychological 
emotions) can increase pain perception. These two feelings are, thus, unwanted in the painful 
patient (Dugdale, 2010). 
In order to fully understand the subject, some light must be shed upon the concepts used to 
explain what pain is and its effects on any subject. As it is, the word “pain” is very vague and 
its definition is merely related to sensation. Biologically, the word that relates to pain is 
nociception. Nociception is the whole physiological process through which there is a neuronal 
response to a noxious stimuli, which in the end leads to the perception of pain (from the 
Greek Nocere - Noxious). If this process becomes interrupted, the stimulus doesn’t elicit a 
neuronal response. Thus, a state of analgesia is established. Analgesia is the total absence of 
pain or of the ability to perceive it. This state is very difficult to achieve as, despite being able 
to inhibit the perception or the transmission of noxious stimuli, they still exist and still trigger 
biological processes. What we can usually achieve is hypoalgesia, or a state of reduced 
perception of pain or reduced intensity of the painful stimuli. This can be achieved through 
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the use of drugs or in certain stressful situations, such as a predator attack, due to endogenous 
mechanisms that will be further explained later. This is an important biological function, 
which allows the subject to walk away from the painful event into safety. The opposite of 
hypoalgesia is also possible to occur, especially due to inflammatory reaction. Hyperalgesia is 
an exaggerated pain response to a stimulus due to decreased receptor threshold and increased 
electric impulse production. This phenomenon can occur in the periphery, at the lesion site 
and adjacent structures (peripheral sensitization) or it can occur centrally, perpetuating the 
perceived pain even after the stimulus is removed. Hyperalgesia can become an extreme 
condition, when even non-noxious stimuli elicit a pain response from the subject. This level 
of sensitization is referred to as allodynia. (Viñuela-Fernández et al, 2007; Traquilli, 
Thurmon, & Grimm, 2007; Dugdale, 2010) 
2. Classification of pain 
Different painful stimuli have different origins. Most of the pain we feel originates from 
inflammatory response to some kind of lesion, since the inflammatory mediators activate pain 
receptors at the lesion site. However, nerve damage or excessive dilation of viscera can also 
produce painfully stimuli. Intensity and duration are the most important pain features to its 
classification and allow distinction between physiologic pain and pathologic pain (Dugdale, 
2010). Nevertheless, there are several ways of classifying pain, as seen below. 
2.1. Acute pain 
Pain which results from sudden tissue lesion caused by thermal, mechanical or chemical 
stimuli, which begins abruptly and has a brief duration. This kind of pain can be easily 
abolished by analgesic drugs (Dugdale, 2010).  
2.2. Chronic pain 
Pain that persists over time and that cannot be reduced by adopting a protective behavior. It is 
difficult to treat fully with analgesic drugs, frequently needing a multi-modal approach to its 
treatment (analgesic drugs along with physiotherapy and environment manipulation, etc) 
(Traquilli, Thurmon, & Grimm, 2007).  
2.3. Somatic pain 
Somatic pain occurs on the skin or in musculoskeletal areas of the body. It can be easily 
localized and differs from visceral pain because these areas possess a higher density of 
receptors with small sensitive fields (Lemke, 2004).  
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2.4. Visceral pain 
In opposition to somatic pain, visceral pain is ill-localized, diffuse and prompted by 
mechanical changes in internal organs (distension, ischemia, dilation). These organs have a 
low density of receptors and each receptor has a larger sensitive field than the somatic ones, 
thus being less specific (Lemke, 2004). 
2.5. Neuropathic pain 
Neuropathic pain can be recognized when the patient’s pain cannot be diminished by normal 
pain medication (medication used to reduce inflammatory pain). It is originated by nerve 
lesions, which result in ectopic activity due to the accumulation of sodium channels in the 
lesion site. This accumulation can spread to the neuronal bodies in the dorsal ganglia and to 
other neurons, including effector neurons. It all might result in spontaneous pain and in 
increased sensitivity in the peripheral nociceptors (D'Mello & Dickenson, 2008). 
2.6. Psychological pain 
Some patients report pain perception even when no lesion can be seen or detected. These 
cases can be related to psychological pain – a phenomenon usually occurring after extreme 
episodes of pain which, through severe neuromodulation of the pain pathways, keep occurring 
despite the treatment and disappearance of the initial lesion (Dugdale, 2010). 
2.7. Adaptative (physiologic) pain 
Physiologic pain is the most frequent type of pain felt and, as the name implies, has a 
physiologic function. Its purpose is to potentiate the subject’s survival by enacting protective 
behavior. This will prevent further damage to the affected area and allow the subject to 
recover into full health. This type of pain requires the activation of high-threshold receptors 
(nociceptors) and it is an adaptive pain, well localized in time and space, and its electrical 
impulses are conducted through A-δ fibers.  (Bishop, 1980; Lemke, 2004; Viñuela-Fernández 
et al, 2007; Hellyer et al, 2007; Dugdale, 2010) 
2.8. Maladaptative (pathological) pain 
Maladaptive or pathological pain, as the name suggests, is a disease. It is triggered by severe 
trauma or other highly painful events (like a car crash or surgery) and its presence is highly 
debilitating to the subject. It generates morbidity and is often difficult to abolish. Besides the 
normal nociceptors, silent receptors (normally associated with non-painful stimuli, like tactile 
sensation) with low excitement thresholds are also activated, increasing the number of 
electrical signals produced. This creates a diffuse pain sensation that is difficult to localize, 
isn’t specific to any stimuli (as it may continue even after the initial stimuli has ended) and is 
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slowly adapting. The electrical impulses that are responsible for pathological pain are 
conducted by C fibers. (Bishop, 1980; Lemke, 2004; Viñuela-Fernández et al, 2007; Hellyer, 
et al., 2007; Dugdale, 2010) 
The veterinarian surgeon must act in every instance where a patient feels pain, but it is in 
pathological pain cases that his action is life-saving, as it is a condition that will not go away 
on its own. Hence, the veterinarian must ease and, preferably, prevent pathological pain from 
occurring to the best of his abilities. (Bishop, 1980; Lemke, 2004; Viñuela-Fernández et al, 
2007; Dugdale, 2010) 
3. The physiology of pain 
3.1. Pain pathways 
Nociception is a sequential process beginning at the level of nociception receptors through the 
transduction of physical or chemical stimuli to electrical impulses and continuing with their 
conduction by an afferent neuronal pathway up to the dorsal horn of the medulla. From here, 
the impulses are transmitted to the spinal and supraspinal centers, where modulation and 
perception of the stimuli occur. Nociceptive pathways are a very complex system. However, 
its structure can be explained in a rather simplistic manner, to allow for a better understanding 
of the path an electrical impulse must go through. There are three levels of neurons by which 
the nociceptive stimulus is transmitted: the primary neurons, the projector neurons and the 
supraspinal neurons (D'Mello & Dickenson, 2008; Dugdale, 2010). 
The primary neurons (also called afferent neurons) have their cellular body located in the 
ganglia of the dorsal root of the medulla and its axons extend peripherically to their target-
organs and centrally to the dorsal horn of the medulla. These neurons connect with specific 
sites on the dorsal horn, which is divided in six lamellae whose function is to process the 
incoming information. The neurons with specific (nociceptive) information link with lamellae 
number one and two (the most superficial), while the more unspecific neurons link with the 
deepest lamellae (Figure 1) (D'Mello & Dickenson, 2008).  
The projector neurons receive the electrical sign from the medulla and establish the 
connection with the spinal and supra-spinal centers (thalamus, pons, midbrain, hypothalamus, 
etc). Then, the supra-spinal neurons take the nociceptive impulse even further into the brain, 
more specifically to the cortical and sub-cortical centers, where perception occurs.  (Lemke, 
2004; Viñuela-Fernández et al, 2007; D'Mello & Dickenson, 2008; Dugdale, 2010)   
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Figure 1 - Pain pathways from periphery to brain. (D'Mello & Dickenson, 2008) 
Image description: The primary afferent fibers lead impulses towards the dorsal root ganglion 
(DRG) and into the dorsal horn of the spinal cord. The superficial dorsal horn is divided into several 
laminae. The most superficial laminae (I and II) contain the nociceptive specific cells (NS), while the 
deeper laminae have the wide dynamic ranges cells (WDRs; lamella V). The parabrachial area (PB) 
and the periaqueductal grey (PAG) are innervated by projection neurons from lamina I and are also 
affected by limbic areas. From these areas and some brainstem nuclei (i.e. rostral ventromedial 
medulla - RVM), the descending pathways have their origin (yellow arrows) and are activated to 
modulate spinal processing. Lamina V neurones mainly project to the thalamus through the 
spinothalamic tract  and from here the various cortical regions forming the ‘pain matrix’ are 
activated. 
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3.2. Pain processing  
Upon establishing contact with a noxious stimuli, a series of events occur almost 
simultaneously, which transform the stimuli into an electrical signal and conduct it towards 
the highest neuronal centers, where the signal is read, perceived and an appropriate answer is 
activated (Lemke, 2004; Traquilli, Thurmon, & Grimm, 2007; D'Mello & Dickenson, 2008; 
Dugdale, 2010). These events can be divided in four stages as follows: 
3.2.1. Transduction 
If the intensity of a stimulus is sufficient to overcome the nociceptor’s activation threshold, it 
triggers a response and the physical energy is transformed into an electrical signal. The 
transduction is thus the initial step that leads into pain perception.  
3.2.2. Transmission 
This stage comprises the conduction of the electrical signal throughout the neural pathways to 
the highest neuronal centers. It is done by pain fibers (A-delta fibers for acute pain and C-
fibers for chronic pain) primarily towards the dorsal horn of the medulla, then to the thalamus 
and reticular system and finally to the cortex and higher centers. However, before reaching 
the higher centers, the signal goes through a stage of modulation. 
3.3.3. Modulation 
At the dorsal horn of the medulla and supraspinal levels, the pain signals are subject to some 
modifications derived from the endogenous descending pathways. This occurs at several 
levels and the descending pathway system is responsible for increasing, decreasing or 
somehow altering the nature of the stimulus. This step is responsible for the complexity of the 
relation between formation of stimuli and their perception, as some of them might get 
nullified by the descending pathways’ intervention. The result of signal modulation is 
dependent on the careful balance between excitatory and inhibitory impulses.  
3.3.4. Perception 
When the noxious signals reach the highest neuronal centers, perception of the stimulus 
occurs. The conscious, subjective and emotional experience of pain is felt at this level only. 
Hence, perception of a painful stimulus is totally dependent on the successful transduction, 
transmission and modulation of the signal.  
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3.4. Ascending pathways 
3.4.1. Afferent fibres and their nociceptors 
Conduction of the electric signals is made through a number of nerve axons grouped together 
to form fibers. Three different types of fibers exist, which differ in composition and in the 
type of electrical signal that travels within them. Not all of these fibers participate directly in 
pain transmission, but all of them are needed to perceive the exact nature of the stimulus.  
A-β fibers are related to non-painful stimuli, like tactile sensation. Due to their large diameter 
and myelinated membrane, these are the fastest transmission fibers. Despite not being used in 
normal transmission of pain, they help in determining its nature. Still myelinated, but with a 
thinner diameter, A-δ fibers carry pain impulses generated by mechanothermal stimuli. These 
fibers respond to extreme changes by these types of stimuli, transporting the electric signals at 
high-speed (3 – 30 m/s) to the medulla. Pain sensation induced from these fibers is called 
epicritic pain and is usually acute (first pain), well localized and adaptative (Lemke, 2004; 
D'Mello & Dickenson, 2008). Finally, the thinnest fibers, C fibers, are the slowest in signal 
conduction and are not coated with myelin. Their receptors are polymodal, meaning that they 
respond to any kind of stimuli, as long as it is sufficient to overcome their high threshold 
level. Conducting speed is less than 3 m/s and the pain transmitted by them is slowly 
adaptative (prolonged in time), diffuse and unspecific. Pain transmitted through these fibers is 
also called protopathic pain. Along with A-δ and A-β fibers, the three fibers are called ‘pain 
fibers’. There is also a less known type of fibers that usually doesn’t take part in any process, 
until an inflammatory response is formed. The ‘silent fibers’ do not respond to stimuli until 
the moment of their activation by inflammatory mediators. From then on, their excitement 
thresholds are sufficiently lowered to be activated by mechanothermal stimuli. These fibers 
are similar to C-fibers, since the pain transmitted by them has the same characteristics as the 
latter. Despite the name, they have an important role in peripheral sensitization, increasing the 
pain sensation at the target site (Lemke, 2004; Viñuela-Fernández et al, 2007; D'Mello & 
Dickenson, 2008; Dugdale, 2010). 
3.5. Descending pathways 
Descending pathways carry impulses generated in the brain. These impulses may have 
excitatory or inhibitory nature, thus increasing or decreasing stimuli transmission. Inhibitory 
descending stimuli are strong enough to prevent pain signals from reaching the brain, thus its 
interest to medicine. Pavlov’s experiments demonstrate a perfect example of the descending 
inhibitory pathway at work: the dogs, before presentation of food, were hurt with electrical 
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shocks or cut in the nose or paws. Despite the noxious stimuli, after a period of habituation, 
they either showed no signal of perception of pain or stopped interpreting these stimuli as 
painful, interpreting them instead as a pre-feeding signal (Melzack & Wall, 1965; Lemke, 
2004). 
Descending inhibitory pathways work at four different levels: cortex and thalamus, 
midbrain’s periaqueductal gray matter, raphe magnus nuclei in the pons and medulla 
oblongata plus spinal medulla. The most important and better understood of them all is the 
periaqueductal gray matter (Dugdale, 2010). 
3.5.1. Periaqueductal gray matter 
This descending pathway is very important due to the high concentration of opioid receptors. 
Its effect is most potent against pain impulses at spinal level. However, they must be activated 
by GABA, serotonin, glutamate, noradrenaline, acetylcholine, adenosine or endorphins to 
work. By identifying the molecules that activate this pathway, doors to the discovery of new 
tools to fight against pain will be opened (Dugdale, 2010). 
3.6. Pain modulation 
Neuromodulation is one of the SNC’s responses to long-lasting pain. Pain perception 
mechanisms can be changed by the presence of painful stimuli. The two biggest phenomena 
that can be observed due to this biologic behavior are sensitization and dessensitization 
(Dugdale, 2010).  
3.6.1. Dessensitization 
It is a physiological way of the organism to deal with frequently felt low-level pain. As 
referred earlier, this process increases the threshold to a certain type of stimuli and prevents it 
from triggering the nociceptors. It can completely negate a painful stimulus or merely 
attenuate its intensity. This property is easily seen when comparing pain thresholds of a senior 
to a junior animal. As the subject grows older, it becomes desensitized to a number of stimuli 
which improve the subject’s survivability. However, this phenomenon may not always occur 
and the reasons or necessary conditions for its occurrence are still unknown (Dugdale, 2010). 
3.6.2. Sensitization 
As an opposite of desensitization, this process’ outcome is the increased perception of a 
painful stimulus. The pain threshold is lowered for a certain stimuli, increasing its intensity. It 
can be divided in peripheral and central sensitization (Dugdale, 2010). 
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3.6.2.1. Peripheral sensitization 
As the name implies, this process occurs peripherally, at the wound site. The presence of 
inflammatory mediators (prostaglandins, histamine, serotonin, substance P) and other 
algogenic agents (H
+
 and K
+
 ions) lowers the thresholds of the silent fibers and nociceptors, 
resulting in an increase of electric signal emission. This prolonged and more intensive 
activation of receptors ultimately results in the increased perception of pain at the wound site, 
which spreads to the lesion’s adjacent areas  (Gogny, 2006). 
3.6.2.2. Central sensitization 
This occurs at a central level, in the SNC. Any pain stimulus can cause central sensitization, 
but long-lasting changes are mostly caused by prolonged, high-intensity and/or high-
frequency stimuli. These stimuli cause a reaction of the raquidian nociceptive neurons, which 
start reacting in an excessive way to the received signals (wind-up). The wind-up effect can 
be so dramatic that pain continues even after removal of the initial stimulus (Gogny, 2006). 
Several molecules are involved in central sensitization, particularly glutamate, which is a 
neurotransmissor that can link to NMDA (N-Metil D-Aspartate) and AMPA (α–amino–3–
hidroxi–5–metil–4–isoxazol-proprionate acid) receptors. These receptors are associated and 
emit long and short duration stimuli, respectively. Central sensitization can be reversed 
naturally after the removal of painful stimulus or with medication, but despite the 
advancements in pain management medicine it remains a very difficult condition to treat. The 
only way of effectively treating central sensitization is by preventing pain (pre-emptive 
analgesia). (Gogny, 2006; Dugdale, 2010)  
3.6.3. NMDA and AMPA receptors 
AMPA receptors are responsible for the establishment of a base response from the medulla to 
painful and non-painful stimuli. They control ion flux and channels of rapid activation by 
glutamate. If the received stimuli arrive from C fibers and possess high intensity and 
frequency, then NMDA receptors are also activated (Viñuela-Fernández et al, 2007).  
NMDA receptors control non-specific cation flux channels in nervous cells (Na
+
 and Ca
2+
 
influx and K
+
 efflux) and indirectly control gene expression, cellular signaling and receptor 
synthesis. These receptors may be found in great concentration in the dorsal horn of the 
medulla (Viñuela-Fernández et al 2007). They are unique receptors, due to their double-
activation mechanism: in order to become active, NMDA receptors need to be subject to a 
persistent membrane depolarization, which will alter their conformation and release Mg
2+
 ions 
from the active site in order to allow the linkage of glutamate and glycine (co-agonist). Influx 
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of sodium and calcium ions through the opened ion channels will perpetrate membrane 
depolarization and initiate cellular signaling cascades that are responsible for long-term 
neuromodulation. These channels remain open for a longer period than normal ion channels, 
thus being perfect for the neuromodulation role. (Viñuela-Fernández et al, 2007; D'Mello & 
Dickenson, 2008; Dugdale, 2010) 
Antagonist molecules to NMDA receptors (ketamine, petidine and some methadone isomers) 
were discovered by modern medicine and their success has been proven (Dugdale, 2010). 
Dextrometorphane and memantine may also antagonize them (D'Mello & Dickenson, 2008). 
All of them are used in an attempt to revert central sensitization. Other possible effective 
molecules include nitric oxide, xenon and benzodiazepines (Dugdale, 2010). Despite their 
properties, the therapeutical window is extremely small and their adverse effects make their 
use a very difficult matter (D'Mello & Dickenson, 2008).  
3.7. New approaches to central pain management 
Hefti et al tested the theory that the nerve growth factor (NGF) is essential in pain signaling 
after lesion and inflammation. NGF antagonist molecules were used in some animal models 
with good results, showing high effectiveness with no adverse effects (Hefti, Rosenthal, & 
Walicke, 2006). 
Glutamate receptors such as AMPA and NMDA are seductive targets for pain management, 
but their wide distribution along the CNS prevents the wide and common use of their 
antagonists, due to the generated adverse effects, as can be seen with the use of ketamine, so 
further clinical studies are needed (Viñuela-Fernández et al, 2007). 
4. Pain assessment 
4.1. Pain assessment and evaluation in small animal practice 
Pain assessment in small animals can be challenging, depending on the skill of the observer, 
his relation with the patient, the patient’s normal behavior and the patient’s species. While 
animals like dogs or monkeys express pain in a clear way, other species prefer to hide the pain 
from possible threats. Cats and sheep are perfect examples of such behavior. Also, the exotic 
pet species (i.e. reptiles) are a different challenge, as their primitive neural development 
hasn’t evolved to allow open expression of pain. Finally, owners perceive pain differently, 
according to the species being observed: while lumbar pain is easily recognized by most dog-
owners, the same isn’t true for cat-owners. Diseases like osteoarthritis, intervertebral disc 
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disease and spondylosis are under-diagnosed due to the common thought that the changes in 
behavior occur due to old age rather than pain. Due to all of these reasons, pain assessment 
must be individualized for each patient. The same surgical procedure can cause different 
levels of pain to an adult in comparison to a senior animal, since the older one might feel 
musculoskeletal pain due to surgery positioning, in addition to the normal, predicted pain 
from the procedure itself (Hellyer et al., 2007). 
Pain evaluation is the second challenge in veterinary pain management. Despite the fact that 
the existence of a painful stimulus alters the normal behaviour of an animal (Holton et al, 
2001; Morton et al, 2005; Dugdale, 2010), some of those changes might not be pain-specific. 
In fact, those changes in behaviour are also typical of fear-provoking events or in the presence 
of a predator, in complete absence of a painful condition (Barr, 1998; Chamberset al, 1999; 
Anil, S.S., Anil, L. & Deen, J., 2002; Morton et al, 2005). Furthermore, most behaviour 
changes may not describe the full extent of the pain the animal is feeling; fearful animals may 
be over-expressing their pain or it can be confused with attention-seeking behaviour. With 
such a high chance for error, the medical community has tried over and over again to 
overcome these obstacles and come up with some sort of mechanism to successfully assess 
animal pain. The answer came in the form of pain scales. 
4.2. Pain measurement through scales 
4.2.1. Visual Assessment Scale 
The Visual Assessment Scale (VAS) consists on a 100mm line with limits labeled as “no 
pain” and “worst pain possible” and where the human patient must place a cross at the level 
where his pain is. Very simple to use in any human patient that can hold a pen, this method 
alone provides some help understanding the need for analgesia, but is easily biased by the 
patient (and also easily abused). However, it can be used in conjunction with other scales to 
make the general pain assessment method more sensitive. In animals, it is still useful, though 
the person marking the scale is the observer. If the observations are repeatedly done by the 
same trained observer, the usefulness of this method is significant. (Holton et al, 1998; Anil, 
Anil, & Deen, 2002; Morton et al, 2005) 
4.2.2. Numeric Descriptive Scale 
The Numeric Descriptive Scale (NDS) can also be used by the observer and is composed of 
several classes with a descriptor and the observed pain should fit into one of those. These 
descriptors can be something as simple as “soft pain, mild pain and strong pain” or have more 
or less descriptors. Usually the classes are numbered and, if several classes are present, the 
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score is added up. Patients scoring over a certain value are considered to be eligible to receive 
analgesia or to have their analgesia protocol reviewed. (Holton, et al., 1998; Anil, Anil, & 
Deen, 2002; Morton et al, 2005) 
4.3.3. Composite pain scales 
The above methods, however, didn’t prove sufficient to identify all painful patients, as they 
aren’t specific enough or the inter-observer variability can be too high (Holton et al., 1998). 
Furthermore, the task of attributing a specific class to a patient might be a difficult one, when 
the pain perceived by the observer might be simultaneously on the high-side of one class or in 
the lower-side of the next class. Sometimes the observer attributes an inconsistent and 
variable gap between classes, which makes the NDS a non-interval scale (Morton et al, 2005).  
Figure 2 – Detail of neonatal pain scale. (Hummel P, 2008) 
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A different approach should be used and the first steps were taken in human pediatric care 
(Figure 2). Human doctors have similar difficulties to identify pain in newborns as 
veterinarians have with animals, since they also are unable to speak. For these pediatric 
patients, several scales were built and tested, which relied on facial expressions and 
describing the way they cried to try and perceive when a neonate would be in pain (Peters et 
al, 2003). Though far from perfect, this method of pain assessment proved very fruitful and 
able to identify most instances when analgesia was required. The same type of observation 
was used for animals in several instances, originating several composite pain scales. 
4.3.3.1. University of Melbourne Pain Scale (UMPS) 
The main objective of this scale is assessing post-operative pain in dogs. The authors used 
ovariohysterectomy (OVH) as the surgical procedure in the test groups (3 test groups, with 
different post-operative analgesia protocols: carprofen, butorphanol or no analgesia), with two 
witness groups that only underwent anesthesia and were medicated either with only 
acepromazine maleate or with acepromazine plus butorphanol. The scale includes 
physiological measurements (heart rate, respiratory rate) and several behavioural responses 
(response to palpation, activity, mental status, posture, and vocalization) (Figure 3). The 
authors proved that the scale was accurate to detect pain and to differentiate pain levels 
between groups and it was also reproducible by different observers. This scale, though, is 
only fit to assess acute pain post-operatively and it was created and experimented in animals 
undergoing elective surgery, meaning that it might not give reliable results when evaluating a 
patient that has undergone different procedures or whose pain is from different origin (i.e. 
somatic pain) (Firth & Haldane, 1999). 
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Figure 3 - University of Melbourne's Pain Scale 
 
4.3.3.2. Glasgow’s Composite Measure Pain Scale (GCMPS) 
This scale was built on a general use basis. It can be used by trained and untrained people 
alike, with any kind of acute pain, originated either from orthopedic or soft tissue surgery, 
trauma or a simple medical intervention. The authors’ objective was to create a valid and 
objective way of assessing pain in the clinical setting using an interval system, so that it is 
valid in any kind of intervention. Based on the McGill’s pain questionnaire and on pre-
existing veterinary pain scales, their defects and strong points were analyzed in order to make 
one cohesive scale, easy to use, with strictly determined wording that reduces inter-observer 
variability as much as possible. The initial study resulted in 39 behavioral expressions and 8 
physiological parameters, spread through 10 categories, with each of the expressions being 
given an intensity value. The sum of all the values for a single patient translates into its pain 
score and that score is then used as the base for a therapeutic decision (Holton et al, 2001). 
This scale was tested in patients subjected to different procedures (orthopedic and soft tissue 
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surgeries, medical management in the hospital and control group) and its objective was to be a 
valid pain scale to use in any dog or cat in any situation where acute pain might present itself 
and also to allow reliable statistical data to be taken from case studies that involved pain 
assessment. It proved effective at doing so, though it still lacks some sensibility to detect 
slight changes in the pain sensation by an in-dwelling patient (Morton, Reid, Scott, LL, & 
Nolan, 2005). The GCMPS short form can be seen in figure 4.  
 
 
Further studies revealed that physiological parameters are not specific to pain, thus are not 
reliable indicators to include in pain evaluation, so the scale was reduced to 7 classes (Morton 
Figure 4 - Short form of the Glasgow Composite Measure Pain Scale. 
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et al, 2005). This resulted in an easy-to-use scale that has significant sensitivity to assess 
patient’s pain and that has become extremely useful in clinical practice. 
5. Pain pharmacology 
5.1. Physio-pharmacology 
Pharmacological treatment of pain is a much desired path ever since the discovery of several 
target areas where certain molecules are able to interfere with the conduction of the signals 
produced by noxious stimuli. Hence, it is possible to modulate pain signals at four different 
stages of transmission (Dugdale, 2010). 
5.1.1. Noxious signal transduction sites 
If the transformation of the noxious stimulus into an electrical signal is prevented, there is no 
pain. Local anesthetics are used to prevent the activation of nociceptors in the periphery and 
the formation of an electric signal (more information in the Local Anesthetics chapter). 
NSAID’s can also be used to obtain the same result since they reduce the concentration of 
pro-inflammatory molecules on the lesion site, reducing secondary sensitization. Opioids and 
α-2 agonists might have some peripheral effects because receptors for both molecule types are 
evident in the inflamed tissues (Traquilli, Thurmon, & Grimm, 2007; Dugdale, 2010). 
5.1.2. Signal transmission sites 
Once again, the use of local anesthetics is advantageous. These drugs can block specific 
nerves (nerve block), block signals coming from a specific area (line blocks, ring blocks) or 
prevent the arrival of the signal to the central neurons in the medulla (regional blocks). This 
type of action blocks the signal transmission to higher centers (Traquilli, Thurmon, & Grimm, 
2007; Dugdale, 2010). 
5.1.3. Signal modulation sites 
Modulation occurs at the medulla and thalamus, where signals can be modified and travel 
further to the cortex. Opioids, α-2 agonists and NMDA antagonists can be used to alter these 
sites’ function. Drugs can be administered systemically or injected directly into the site of 
choice (i.e. epidurals) (Traquilli, Thurmon, & Grimm, 2007; Dugdale, 2010). 
5.1.4. Signal perception sites  
These sites include the cortex, reticular formation and limbic system and are the only point 
where the perception of the pain signals occurs. Medical intervention at these sites is possible 
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through the use of anxiolytics/sedatives (like benzodiazepines and phenothiazines), opioids 
(those with more sedative effects) and even injectable or inhalable general anesthetics 
(Dugdale, 2010).  
5.2. Common analgesic agents used in the perioperative period  
5.2.1. Opiates and opioids 
5.2.1.1. Introduction 
Opiates are derivates from opium, which is extracted from the poppy flower (Papaver 
somniferum), and have important analgesic properties. Morphine was the first substance to be 
identified and is currently the representative of this drug class. All other opioids are compared 
to morphine, in order to assess their relative potency. All drugs from this class are analgesics 
but are also considered narcotics, because narcosis (a feeling of sedation, sleepiness) is one of 
their adverse effects. Opiates are the natural molecules taken from opium; opioids are 
synthetic molecules with a similar mechanism of action to that of opiates. However, opioid is 
the most commonly used expression to refer to this group and will be the one adopted 
throughout this text (Dugdale, 2010). 
5.2.1.2. Mechanism of action 
Opioids take action in the opioid receptors, which are wide spread through the body. These 
receptors were first known to exist in the CNS but more recently were found to exist also in 
peripheral tissues, like the gastrointestinal tract or joint tissue, especially during inflammation. 
Their action differs with the target species, due to different distribution and abundance in the 
tissues. Thus, the same dose of morphine can cause sedation in dogs but may cause euphoria 
(a typical overdose effect) in cats or horses, which have a higher density of opioids receptors 
in the CNS. There is also a variety of different opioid receptors and each molecule has 
different affinity to them (i.e. birds and reptiles have more κ receptors than µ), which means 
the same molecule may provide good analgesia on one species and sub-optimal analgesia on 
another (Epstein, 2012).  
Discovered opioid receptors are: δ receptors, the receptor site for endogenous encephalins; µ 
receptors, the main receptors for opioid molecules, β-endorphins and some encephalins too; κ 
receptors, similar to µ receptors, but with a distribution mainly in the CNS; σ receptors,  once 
considered opioid receptors but now considered to be related to NMDA receptors; ε receptors, 
thought to be endorphin receptors (Dugdale, 2010).  
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The most important effect of opioid drugs occurs against diffuse pain, due to the density of 
receptors being highest in the periaqueductal gray matter, where the inhibitory descending 
pathways are stimulated. Effectiveness against sharp acute pain isn’t very noticeable because 
that type of pain is modulated by the reticular formation, which has low density of opioid 
receptors (Dugdale, 2010; Epstein, 2012). 
5.2.1.3. Classification 
Classification of opioids is based on the interactions with the receptors. Drugs can be agonists 
(full or partial), antagonists or agonist-antagonists to one or more receptors. Opioid agonists 
connect to the receptors and elicit a biological response (with partial agonists being weaker 
than full agonists), while the antagonists trigger no response from the receptors. The latter 
ones are, usually, used as antidotes for opioid overdose or simply to stop their action when 
needed. Agonist-antagonists have a mixed effect, depending on the receptors they connect to, 
and in certain situations they can be used to antagonize a full-agonist (Epstein, 2012).  
Each molecule has different strengths, depending on affinity to receptors, type of activity and 
the density of receptors in the target species. As explained above, all opioids are compared to 
morphine to assess their relative potency. This means that the comparison between them is to 
assess which dose of a certain opioid is able to block a standardized pain signal and then 
compare it to the morphine’s action efficacy (i.e. fentanyl’s dose to block a painful stimulus is 
a hundred times smaller than morphine’s dose to achieve the same effect, thus, fentanyl is a 
hundred times more potent than morphine). This classification is very useful, since it is based 
on clinical efficacy and allows the practitioner to successfully plan his analgesic protocol 
according to the level of pain expected in each procedure. However, other factors must be 
observed, namely the preparations’ physical characteristics (pKa and liposolubility), the route 
of administration and the target species (Traquilli, Thurmon, & Grimm, 2007; Dugdale, 2010; 
Epstein, 2012).  
5.2.1.4. Pharmacokinetics 
Some active metabolites may prolong the effect beyond the original molecule’s expected time 
of action. Opioid metabolism occurs in the liver tissue and excretion is biliary and urinary. 
Thus, practitioners should be cautious of using these molecules in animals with any kind of 
hepatic or renal impairment (Plumb, 2011). 
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5.2.1.5. Expected and adverse effects 
Opioid effects in the CNS result in supraspinal, spinal and peripheral analgesia, along with 
light to moderate sedation. However, as opioid receptors are wide spread along the organism, 
some adverse effects also occur. These are usually dose and molecule-dependent (Dugdale, 
2010).  
Opioid drugs affect the sensitivity of respiratory centers to changes in blood tCO
2
, causing 
respiratory rate depression (bradypnea). This might pose a problem in non-tachypneic 
animals, whose only complaint is pain, though it has been proven that when pain is present 
the respiratory effects are almost absent (McMillan, 2012). 
According to the liposolubility of each substance, opioids can either stimulate or inhibit 
emesis. It depends on whether the molecule used reaches the chemoreceptor trigger zone 
(CTZ) or the emesis centre first, respectively. They might also increase smooth muscle 
motility. However, this effect doesn’t mean faster food transit in the gastrointestinal tract 
(GIT) food transit because the increased motility isn’t coordinated between muscles. 
Exception to this rule is petidine with its anti-spasmolytic effect, along with other 
anticholinergic effects (Dugdale, 2010). 
There are also molecule and species-dependent effects in the cardiovascular system. Rapid IV 
administration of some opioids may induce histamine release with consequent hypotension. 
Hypotension can also be centrally induced by morphine, along with bradycardia, through a 
vago-mimetic effect. However, etorphine and carfentanyl have hypertensive effects (Trim, 
2008; Dugdale, 2010; Epstein, 2012). 
5.2.1.6. Example 1 - Methadone 
This opioid has been known in human medicine for a long time and was mostly used to treat 
opioid addiction, since its withdrawal effects were much less prominent than those of heroin 
or morphine. Similar in effect and classification to morphine (full µ agonist), methadone has a 
longer half-life than her counterpart. Its effects extend beyond the normal opioid effects. It is 
reported to have NMDA antagonist activity, making it useful in some central sensitization and 
chronic pain cases, as well as causing inhibition of the reuptake of serotonin and 
norepinephrine, improving its analgesic activity. Its activity in the NMDA receptors also 
prevents development of tolerance towards opioid effects, a useful fact to keep in mind in 
prolonged opioid administration. Its activity is synergic with the administration of other 
opioids (Riviere & Papich, 2009). 
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Administration of methadone can be done through several routes. It can be given SC, IM or 
IV with increasing availability respectively, and it can even be administrated orally through 
the transmucosal absorption effect in cats (Ferreira et al, 2011). Methadone’s half-life is 
longer than morphine’s due to slower elimination, thus it should be administered in longer 
time intervals than morphine (every six to eight hours against every four hours for morphine) 
(Riviere & Papich, 2009).  
Besides the normal opioid adverse effects, it has been reported increased systemic vascular 
resistance and coronary vascular resistance following administration. Thus, it should be 
carefully dosed and administered in patients prone to congestive heart failure. It also causes 
less vomiting and less excitation than other µ agonists (Plumb, 2011). 
Methadone is commercially available as a 50:50 racemic mixture, but only the L-methadone 
has analgesic properties. However, both L and D enantiomers have affinity to NMDA 
receptors. Levomethadone is composed exclusively of L-methadone and thus, regarding 
analgesia, is more potent than normal methadone. When using levomethadone, doses should 
be halved (Riviere & Papich, 2009).  
5.2.1.7. Example 2 - Buprenorphine 
Buprenorphine is a mixed agonist-antagonist opioid, having agonist properties when linking 
to µ receptors and antagonist properties when linking to κ receptors. In terms of analgesia, 
sedation and side-effects, it exhibits the same effects as all other opioids but it has a plateau 
effect, after which additional doses do not increase intensity of analgesia. It is a safe molecule 
to use, with toxic doses being several dozen times higher than therapeutic ones. Its use along 
with other opioids should be avoided, as buprenorphine has a higher affinity to the µ receptor 
than full agonists, and thus can result in some reversal-like activity, displacing the full 
agonists from the receptors. The positive side of its high affinity is the long duration of action 
(four to six hours). It is approximately thirty times as potent as morphine, but studies on its 
analgesic efficacy differ, some saying that it is lower than morphine, others saying that it is 
higher in the cat. Administration routes include SC, IM, IV and oral transmucosal in cats 
(Riviere & Papich, 2009; Plumb, 2011).  
5.2.1.8. Special case - Tramadol 
Tramadol is a molecule with some resemblance to opioid drugs, but its mechanism of action 
is hybrid, generating both opioid and non-opioid effects. Its potency is about 1/10 of 
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morphine, but it has less adverse effects. Despite its reduced potency, some metabolites are 
more potent than the parent drug (Dugdale, 2010). 
Tramadol’s mechanism of action comprises several mechanisms which include a weak 
agonism to µ receptors as well as weak alfa-2 receptor agonism. It also inhibits synaptic 
reabsorption of noradrenalin and serotonin, while stimulating the release of the latter, which 
contributes to the activation of inhibitory descendent noradrenergic and serotoninergic 
pathways. Last but not least, it has a possible effect in reducing substance P release (Dugdale, 
2010; Plumb, 2011). This range of the effects can be attributed to the different enantiomers 
present in the marketed racemic solution. The positive enantiomer is responsible for the 
opioid-like activity, while the negative enantiomer is responsible for the other mechanisms. 
Its numerous metabolites also play an important role in its efficacy (Riviere & Papich, 2009). 
Adverse effects are limited to nausea, emesis and drowsiness/sedation (Riviere & Papich, 
2009; Dugdale, 2010). Care should be taken in calculating dosages for cats and dogs, as cats 
metabolize the drug more slowly and thus it has a longer duration of action than dogs (12 
hours against 6-8 hours, respectively) (Riviere & Papich, 2009). 
5.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
5.2.2.1. Introduction 
This group is vast and is comprised of drugs which have in common their anti-inflammatory, 
anti-pyretic and analgesic properties. NSAIDs are weak organic acids that can be divided into 
two categories, based on their molecular composition: enolic acids (pyrazolones, 
pyrazolidines and oxicams) and carboxylic acids (salicylic, acetic, proprionic, fenamic and 
nicotinic acids). The only exception to this is paracetamol, which isn’t an acid and, unlike the 
other molecules, has a much better antipyretic action than both analgesic and anti-
inflammatory actions (Dugdale, 2010).  
5.2.2.2. Mechanism of action and main effects 
The mechanism of action of NSAIDs is based on inhibition of ciclo-oxygenase (COX) 
activity, the most important enzyme in the arachidonic acid cascade, preventing the formation 
of several pro-inflammatory molecules, like thromboxanes (TX) and prostaglandins (PGs). 
This inhibitory effect is responsible for the analgesic, antipyretic, anti-inflammatory, 
antithrombotic and antiendotoxemic effects of NSAIDs. Their variety of effects makes for a 
wide use in several different clinical situations. 
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5.2.2.3. Classification 
According to their specificity to either COX-1 or COX-2 (two isoforms of the COX enzyme), 
these molecules can be classified as non-selective, partially COX-2 selective or COX-2 
selective. Theoretically, as selectiveness increases, adverse effects decrease in number and 
severity. However, several studies have proven that this isn’t exactly true and thus the 
interaction between NSAIDs and COX molecules needs to be better understood in order to 
improve the effectiveness of these drugs (Riviere & Papich, 2009; Dugdale, 2010; Plumb, 
2011). 
This theory arises from the fact that COX-1 is associated with physiological functions in the 
organism (by producing PGs that are used in the maintenance of several protecting 
mechanisms of different organs: production of the gastric mucous layer, auto-regulation of 
renal blood flow, etc) and COX-2 participates in the production of pro-inflammatory 
molecules through its action over arachidonic acid. However, it was discovered that COX-2 
also has some physiological functions, participating in angiogenesis of wound healing, for 
example, which indicates that full COX-2 inhibition might not be the way to go. (Riviere & 
Papich, 2009; Dugdale, 2010) 
5.2.2.4. Adverse effects 
Due to their inhibition of both COX isoforms, the effects referred above aren’t the only ones 
that occur. The most known adverse effects of NSAIDs are gastrointestinal hemorrhages or 
ulceration due to the gastric protective mucous layer decreased production. They also have 
renal adverse effects caused by inhibiting the production of maintenance PGs that keep 
optimal renal blood flow and then leading to kidney ischemia. Since they are metabolized 
through hepatic biotransformation, hepatotoxicity might also occur. Salicylic acids and 
ketoprofen’s anti-platelet aggregation properties might be harmful to the patient if 
hemorrhage is present (such as that induced by gastric ulceration). Other adverse effects 
include birth delay and teratogenicity in the fetus of pregnant females. For asthmatic patients 
NSAIDs should be used with care. Most molecules inhibit COX enzymes while not having an 
effect in lipo-oxygenase (LOX) activity, thus favoring tromboxane (TX) production. 
Increased TX production may lead to episodes of severe bronchic constriction (Riviere & 
Papich, 2009; Dugdale, 2010; Plumb, 2011). 
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5.2.3. Local anesthetics 
5.2.3.1. Introduction and classification 
The use of local anesthetics (LAs) for analgesia during surgery under general anesthesia is a 
relatively recent event. Up until now they were used to perform small surgeries in non-
sleeping patients or during a lameness clinical exam in horses, but never considered for use 
along with other analgesia drug classes for procedures such as surgery (Jones, 2002). Their 
use, however, recently extended to epidural anesthesia, intra-operative analgesia and even 
post-operative analgesia, by using a local infiltration technique resorting to a subcutaneous or 
intramuscular-placed catheter (Dugdale, 2010).  
Local anesthetics are weak bases that effectively block sodium (and other) ion channels in the 
peripheral nerves’ membranes, preventing membrane depolarization and, thus, stopping 
electrical signal conduction. Their molecular structure is composed by an aromatic group 
(with lipophilic properties), an intermediate link composed by carbon and hydrogen atoms 
and an amide group (with hydrophilic properties). The nature of the intermediary link allows 
the division of the drugs into an ester-linked group (composed by cocaine, procaine, 
tetracaine, etc.) or an amide-linked group (lidocaine, bupivacaine, ropivacaine, etc.). Both 
groups provide good local analgesia though they differ in several properties (see Table 1). 
Local anesthetics are supplied as slightly acidic solutions which contain a higher percentage 
of ionized molecules than non-ionized molecules. Upon administration, the local pH (around 
7.4) quickly normalizes that percentage, depending on the substance’s pKa. Both forms of the 
substance are needed to achieve the nerve-blocking effect (Casati & Putzu, 2005; Riviere & 
Papich, 2009; Dugdale, 2010). 
Table 1 - Comparison of properties between local anaesthetic agent groups (adapted from 
Dugdale, 2010). 
Properties of amino-esters Properties of amino-amides 
Poor tissue penetration Good tissue penetration 
Short duration of action (rapid metabolism) Long duration of action (slower metabolism) 
Fast elimination = decreased chance of 
toxicity 
Slow elimination = increased risk of toxicity 
Increased chance of allergic reactions due to 
para-amino benzoic acid (pABA) as 
metabolite. 
Possibility of allergic reactions due to 
methylparaben as preservative (can break 
down into pABA) 
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5.2.3.2. Mechanism of action 
LAs’ mechanism of action is not completely understood. These drugs are highly liposoluble 
with an alkaline pKa and are rapidly absorbed by the tissues. This allows a quick linkage to 
the sodium channels of the peripheral nerve fibers, blocking their signal conduction 
properties. This block is performed by ionized and non-ionized molecules. Due to their pKa 
(see Table 2), LAs are dissociated into these two forms, which perform the same action 
through different mechanisms. Ionized molecules block the sodium channels from the exterior 
side of the fibers, while the non-ionized molecules are absorbed into the fibers and perform 
the block from the inside. It is important to keep this in mind when using LAs to anesthetize 
an inflamed tissue, because in these conditions the local pH is altered. This may lead to a 
delayed onset of action which needs to be taken into consideration (Dugdale, 2010). 
The three most important characteristics of a local anesthetic are pKa, which controls the 
amount of ionized and non-ionized molecules available after administration and thus regulates 
speed of onset of action; lipid solubility, which relates to a substance’s potency; tissue protein 
binding, which is the property that relates to duration of action. A combination of these three 
properties and also the tissue’s condition regulates the drug’s tissue penetration. (Casati & 
Putzu, 2005; Dugdale, 2010) 
5.2.3.3. Effects and pharmacokinetics 
The complete blockage of impulses in the affected nerves causes a lack of sensation in the 
innervated area and, thus, an absence of pain when certain procedures are done to an 
anesthetized area.  
It must be taken into account, though, that all tissues have sodium channels, with some 
variations in type and density depending on the tissue in question. If a sufficient dose of an 
LA is systemically absorbed, those tissues’ channels will be inhibited, causing depressant 
effects, especially in both the CNS (sedation, seizures, depression, coma, respiratory arrest) 
and the cardiovascular system (cardiac arrest). This fact explains the risk of using high doses 
of LAs. After absorption, the local anesthetic may inhibit the ion channels of a primary organ 
(brain or heart, for instance) and cause severe problems. These effects are more pronounced 
with more lipophilic substances. Vasoconstrictor drugs can be used to delay the systemic 
absorption (lidocaine, i.e.), though the more recent molecules already have a certain 
vasoconstricting effect (bupivacaine, ropivacaine and levobupivacaine) (Casati & Putzu, 
2005). Other adverse effects can arise from nerve toxicity (detergent-like activity of high 
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doses of LAs, preservatives of commercial solutions, excessive vasoconstrictor effect) or 
allergic reactions (especially with ester-linked group molecules). (Riviere & Papich, 2009; 
Dugdale, 2010) 
Table 2 - Physicochemical properties of some local anaesthetic agents. (adapted from Dugdale, 
2010) 
 pKa Onset Relative lipid 
solubility 
Toxicity Relative 
potency 
Protein 
binding 
Duration of 
action 
Lidocaine 7.9 Fast 150 Medium 2 65% Intermediate 
Bupivacaine 8.16 Moderate 1000 High 8 95% Long 
Ropivacaine 8.1 Moderate 400 Medium 6 95% Long 
 
Care should be taken when using LAs in patients with impaired liver function, as all 
molecules are liver-metabolized (Plumb, 2011). 
5.2.3.4 Example 1 - Ropivacaine 
Ropivacaine is an amide-linked local anesthetic with many similarities to the well-known 
bupivacaine. It is very similar to bupivacaine, differing from it for being a pure left-isomer 
and having one less carbon in the side-chain. Left-isomers are proven to be less toxic than 
racemic mixtures or right-isomers. Also, the reduced number of carbons in the side chain 
makes it less lipophilic than bupivacaine. These two characteristics explain the advantages of 
ropivacaine compared to its predecessor: less inherent CNS and cardiovascular toxicity 
(which makes it a safer drug to use, in case large volumes are needed), less systemic 
absorption (due to its lower liposolubility, it is harder to cross the blood-brain-barrier and 
leads to the next advantage) and increased duration of action (because it remains in the target 
area for a longer period of time)  (Casati & Putzu, 2005; Dugdale, 2010).  
In terms of potency, it is classified as being 50% less potent than bupivacaine, in controlled 
trials. However, in clinical studies, this difference isn’t relevant. In fact, it is noticed that 
ropivacaine blocks produce the same analgesia (although the doses are 50% higher than 
bupivacaine) but less motor blockage, which allows for an earlier recovery of the patients. 
This remains true only as long as 0,5% or 0,75% concentrations of ropivacaine are used 
(Casati & Putzu, 2005).  
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5.2.4. α-2 receptor agonists 
5.2.4.1. Introduction 
Composed by xylazine, detomidine, medetomidine and dexmedetomidine, among others, this 
drug class is very well known and used around the globe by physicians and veterinarians alike 
ever since they came around in the 20
th
 century. However, after the discovery of 
medetomidine and even dexmedetomidine, along with the increasing worries about managing 
pain during procedures, practitioners began to use them with more frequency due to their 
excellent combination of sedative and analgesic properties (Kraus, 2012). They are seldom 
used alone for any anesthetic protocol. Usually, α-2 agonists (A2As) are used in conjunction 
with opioids, benzodiazepines or other tranquilizers/sedatives for a greater sedation effect, 
longer duration of action and reduced dosages of all substances. A2As and opioids have 
synergistic analgesic effects that should be taken advantage of. Finally, the use of A2As with 
general anesthetics highly reduces the dosage needed to achieve the target plane of anesthesia, 
both with fixed and inhalable drugs (propofol, thiopental, isoflurane, sevoflurane, etc…). 
With high doses of dexmedetomidine, inhalable anesthetic needs can be reduced as much as 
89% (isoflurane; in dogs, with a 20 mcg/kg/IV dose) (Teixeira-Neto, 2009).  
5.2.4.2. Mechanism of action and main effects 
A2A’s connect to the adrenaline receptors across the central and peripheral nervous system 
and displace norepinephrine from there, creating a negative-feedback that prevents adrenaline 
release and the propagation of stimulus. However, because these receptors are not limited to 
the nervous system, when they connect to the cardiovascular receptors they also cause 
peripheral vasoconstriction that increases systemic blood pressure, while reflexively lowering 
heart rate. Vomiting might also be seen in some patients (Plumb, 2011; Shaffran, 2012).  
Alfa-2 antagonists can be used to control adverse effects and the duration of sedation. The 
most common drug used is atipamezole, which is safe and guarantees an effective reversal 
effect in a short period of time (usually 5-15 minutes). Yohimbine and tolazoline might also 
be used, but they often come with undesired side effects, since besides displacing the 
agonists’ molecules from the receptors, they also stimulate the CNS. Atipamezole has no 
effect on CNS, thus making it the safer choice, as well as having a longer duration than 
dexmedetomidine which prevents the re-sedation effect (animals becoming sedated again 
after the antagonists’ effect has run off) (Shaffran, 2012). 
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Their action at the adrenergic receptors in the locus coeruleus and spinal cord is responsible 
for their sedative and analgesic properties. Most A2A’s also act at the imidazoline receptors, 
this site being responsible for their anti - arrhythmogenetic effect (Shaffran, 2012).  
5.2.4.3. Adverse effects and pharmacokinetics 
Adverse effects are related to the agonistic action on the α1-receptors, which translate 
especially into an excessive bradycardia or excessive hypertension, usually present when a 
high dose of one of the drugs is administered. Respiratory depression is usually not seen in 
healthy patients but may be an issue in ill patients. Nonetheless, oxygen supply should be 
available because some patients have an important reduction in O2
 
blood saturation, after 
being given a high dose of A2A (Traquilli, Thurmon, & Grimm, 2007; Teixeira-Neto, 2009; 
Dugdale, 2010; Plumb, 2011). 
A2As are mostly excreted in urine, thus the veterinarian needs to be careful when using these 
in animals with impaired renal function. Patients with known cardiac disease or with liver 
function impairment are not eligible for an anesthesia protocol involving A2As.  
5.2.5. NMDA antagonist - Ketamine 
5.2.5.1. Introduction 
Ketamine is the shortest acting phencyclidine derivative, with tiletamine being a longer 
lasting version of it. It is widely used in veterinary medicine due to the dissociation effect 
seen between the thalamocortical and limbic systems. Plus, ketamine has a potent analgesic 
effect, which labels it as a very useful tool to use in analgesia protocols. It is also one of the 
few molecules able to lessen or even reverse the central sensitization phenomenon (Riviere & 
Papich, 2009).  
5.2.5.2. Mechanism of action and pharmacokinetics 
Ketamine acts as a non-competitive antagonist of the NMDA receptors, preventing their 
activation by connecting to a specific site inside the receptor (phencyclidine binding site) and 
physically blocking Ca
2+
 entrance. Besides this, it also has antagonist effect in µ opioid 
receptors, agonist effect in κ and δ opioid receptors, granting it some opioid-like analgesic 
effects, and even on monoaminergic and muscarine receptors and voltage-sensitive calcium 
channels, which explains the effects in the cardiovascular system, respiratory system and 
muscular tone (Riviere & Papich, 2009; Dugdale, 2010; Plumb, 2011). Anesthesia with these 
agents causes a state of altered consciousness, also known as catalepsy. This means that the 
28 
 
 
patients are aware of their surroundings but they stop caring about it and cease responding to 
the stimuli. Dissociative agents are also analgesic and prevent/revert central sensitization 
effects (Dugdale, 2010). 
Ketamine is mainly metabolized in the liver, but in cats it is excreted almost in nature through 
the urine. Thus, it should be used cautiously in dogs with hepatic or renal disease and in cats 
with renal impairment (Plumb, 2011).  
5.2.5.3. Adverse effects 
Ketamine’s adverse effects are related to its use in patients who have diseases of the organs in 
which it acts, with exception to the wake-up delirium that patients go through. It can be 
dangerous for the patient and for the people handling it, so drugs that counter this state of 
mind should be administered in conjunction with ketamine (i.e. benzodiazepines). This drug 
has some contra-indications like: it should not be used in head trauma patients or any patient 
with a disease that involves increased intra-cranial pressure, as the administration of ketamine 
increases it; patients with diagnosed hypertension are not eligible for anesthesia with this drug 
due to the increased sympathetic tone granted by ketamine; finally, patients with renal failure 
might experience a longer duration of a ketamine administration (Riviere & Papich, 2009; 
Plumb, 2011).  
5.3 Multimodal and pre-emptive analgesia 
Several years ago, during the advent of analgesia as a discipline, the analgesic protocols were 
very simplistic. They were often composed of single drugs (the number of available drugs was 
also much lower than nowadays) and their dose was titrated to effect. In some patients, the 
dose would be so high that the adverse effects of the drug used would become serious 
considerations before or during the procedure. As new drugs were discovered and new studies 
were made, a better understanding of the mechanisms of pain and analgesic drugs was 
obtained and the use of a mixture of drugs to fight pain was attempted. The results were great 
and it slowly became the norm. Multimodal analgesia (the use of several analgesic drugs in a 
single analgesic protocol) is an almost mandatory step in our days, as the benefits highly 
surpass the risks of mixing several drugs in the patient. Since the pain pathway is blocked or 
intercepted in several different points, the pain signals find a series of impassable hurdles, 
thus successfully preventing the signals from reaching the highest brain centers. Furthermore, 
the use of several analgesic drugs allows a major reduction of each drug’s dose, greatly 
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reducing the occurrence of adverse effects and allowing the fine tuning of analgesia depth to 
our desired purpose. (Gogny, 2006; Hellyer et al, 2007) 
The concept of prevention of pain has evolved even more, though. In modern days, we also 
recur to Pre-emptive Analgesia, or the administration of analgesic drugs prior to a painful 
procedure. In theory, if the analgesic agents are already present in the organism when a 
painful stimulus occurs, the painful signal will be almost immediately suppressed by their 
action, since the steps of administration and distribution of the drug in body tissues are 
skipped. Furthermore, since the only way to prevent peripheral and central sensitization is to 
successfully prevent any nociceptive signal to reach the highest centers, this procedure seems 
to be the only one that can avoid them. However, many controversial studies are published 
and a general consensus about this pain management strategy hasn’t been reached. (Victory et 
al, 1995; Vallejo et al, 2006; Viñuela-Fernández et al, 2007; Rica et al, 2007; Bamigboye & 
Justus, 2008) 
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Part II – Experimental study 
1. Introduction 
General anesthesia and opioid plus non-steroidal anti-inflammatory drug combinations are 
often used in surgical procedures, as tools of guaranteeing patient immobility and preventing 
pain. The principles of multimodal analgesia state that different drugs should be used in order 
to interrupt the pain pathways at several levels and thus prevent central sensitization 
successfully. Secondly, if under the effect of a drug the transformation of a painful stimulus 
into an electrical signal is prevented, then pain sensation is blocked at the beginning of the 
pain process and all of its effects are prevented. This is the key concept behind the use of local 
anesthetics, drugs that have been known to veterinary medicine since the 1890’s (Riviere & 
Papich, 2009). However, their use in combination with general anesthesia wasn’t described 
until 2000 (Nolan, 2000). After this description, there has been a growing interest in the utility 
of this kind of approach to peri-operative pain and a multitude of drugs and infiltration 
techniques have been tested in order to assess which of them might be the most useful in a 
certain procedure. 
The inclusion of local anesthetics like lidocaine and bupivacaine in analgesic protocols for a 
variety of procedures has been tested in several studies and although the theoretical reason for 
their success is clear, results have been surprisingly controversial (Victory et al, 1995; 
Carpenter et al, 2004; Casati & Putzu, 2005; Vallejo et al, 2006; Savvas et al, 2008; 
Bamigboye & Justus, 2008; Campagnol et al, 2012;). The use of these drugs brings great 
benefits regarding pain management, but their side-effects must always be taken into account, 
especially when considering patients with underlying heart or CNS diseases, since the 
possibility of interfering with the normal electrical function of the heart due to an over-dosage 
of local anesthetic is real and often irreversible. Through extensive retrospective analysis of 
several studies regarding the differences between bupivacaine, levobupivacaine and 
ropivacaine, it was concluded that despite the differences in their relative potency at a 
molecular level, there doesn’t seem to be a significant difference between their effects, 
determined by the degree of success of the procedure, following administration of one of 
these drugs (Casati & Putzu, 2005). Furthermore, ropivacaine has a safer profile compared to 
bupivacaine (Casati & Putzu, 2005; Riviere & Papich, 2009). It becomes obvious that there is 
interest in generalizing the use of this drug, in order to obtain safer protocols.  
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Several studies of ropivacaine’s effectiveness exist in human medicine (Rica et al, 2007; 
Bamigboye & Justus, 2008; Gutton et al, 2013;), which might indicate that its analgesic 
properties and safer profile can be used safely in animals as well. Since its use has been so 
restricted, its usefulness hasn’t been tested in the full range of existing surgical procedures, 
with most of its use being concentrated in laboratory trials (Feldman et al, 1997; Takahashi, et 
al., 2004; Charlet, Rodeau, & Poisbeau, 2011; Loon et al, 2012) and clinical studies (Klein & 
Benveniste, 1999; Marzo et al, 2012), in procedures ranging from epidurals, intravenous 
regional anesthesia, cervical blocks or braquial plexus blocks.  
Furthermore, in the Veterinary Teaching Hospital of the University of Helsinki, the surgical 
team has great care in assuring that their patients are given the best and most appropriate 
anesthetic protocols to their surgeries. Lately, they’ve been trying to develop a better 
analgesic protocol for ovariohysterectomies, since they felt their protocol was lacking and that 
they could give a better post-operative comfort level to their patients. Thus, several ideas have 
come up, from instilling local anesthetic before the ligature of the ovarian pedicles to the use 
of a local anesthetic to alleviate abdominal pain during the post-operative period. The author 
then decided to contribute to this research by picking up one of the suggestions (the local 
anesthetic administration) and studying its efficacy. As for drug choice, the lack of available 
information on ropivacaine for its use in more routine procedures led the author into 
designing a study with which a contribution to this gap in medical knowledge could be given. 
2. Objective 
This was a blind, randomized controlled clinical trial. Its objective was to assess the 
effectiveness of a subcutaneous infiltration of ropivacaine over the incision line in preventing 
post-operative pain, in healthy female dogs after elective ovariohysterectomy (OVH). More 
specifically, the objective was to determine if the group treated with ropivacaine had lower 
pain scores than the group that only received a saline administration. 
The experimental protocol was submitted to and approved by the Animal Ethical and Welfare 
Committee of FMV-ULisboa. 
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3. Material and Methods 
3.1 Patients and inclusion criteria 
The study was performed at the HEFMV-ULisboa. A total of 15 female dogs that were 
scheduled for elective ovariohysterectomy were selected for this study, based on the data 
gathered at the pre-surgery consultation. Patient info can be seen in table 3. Inclusion criteria 
included age between 6 months and 9 years old, weight between 2.5 and 50 kg and to be 
healthy and non-pregnant as determined by anamnesis, physical exam and basic blood 
analysis (haematocrit, total proteins, glucose, ALT and urea). Any alterations in any of the 
parameters meant exclusion from the study. One of the patients was excluded from the study, 
as explained below. 
Patients were kept in a separate recovery room from the other surgery patients, where the 
observer had easy access to them and could easily monitor them. All patients were walked 
outside at least once during the study. 
Table 3 - Patient list and respective study group. 
Group Patient 
nº 
Age  Breed Weight 
(kg) 
NaCl 
1 1 year French 
Bulldog 
11,4 
4 8 mo. X Husky 19,6 
5 2 years Jack russel 4,5 
7 1 years SRD 23,6 
8 5 years SRD 7,2 
11 1 year SRD 19,3 
13 10 mo. SRD 11,8 
Ropi 
2 9 mo. SRD 7 
3 3 years SRD 10,4 
6 9 mo. SRD 15 
9 6 years Boxer 31,3 
10 1 year Yorkshire 2,7 
12 1 year Yorkshire 3,1 
14 2 years French 
Bulldog 
10,5 
3.2 Study groups 
After approval into the study, dogs were divided randomly into two groups: Group 
Ropivacaine (GR) and Group Saline (GS). The observer was blinded to patient distribution 
during the study. Both groups were subjected to an SC administration over the incision line, 
during surgery preparation, approximately 15-20 minutes prior to surgery start. GR got 1 
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mg/kg ropivacaine and GS got the same volume of saline. Aside from this, both groups 
received the same anesthetic protocol. 
3.3 Therapeutic protocol 
Patients were pre-medicated with 0.2 mg/kg of methadone (Semfortam
®
, Eurovet animal 
health B.V., Bladel, Netherlands) and 0.01-0.02 mg/kg of acepromazine (Calmivet
®
, 
Vétoquinol SA, Lure, France) 15 to 30 minutes before being taken to preparation. Patients 
under 10 kg of weight were not given acepromazine. Once in preparation and after catheter 
placement, induction was attained with 2 – 4 mg/kg of propofol (Lipuro®, BBRAUN Vet Care 
SA, Rubí, Spain) and intubation was performed. Maintenance of anesthesia was achieved with 
isoflurane (IsoVet
®
, BBRAUN Vet Care SA., Rubí, Spain). After induction, all patients 
received 12.5 mg/kg amoxycilin plus clavulanic acid subcutaneously (Synulox
®
, Pfizer Italia, 
S.r.I., Latina, Italy). The local anesthetic block was performed during the site washing and 
disinfection. GR received 1 mg/kg of ropivacaine (Naropeine 0,5%
®
, AstraZeneca Produtos 
Farmacêuticos Lda., Barcarena, Portugal) and GS received a volume of saline (Soro 
fisiológico BBRAUN Vet Care SA, Rubí, Spain) calculated using ropivacaine’s dose and 
concentration. Rescue analgesia was given to all dogs in this study, either at the end of the 
monitoring period (6 hours post-local block) or if they scored over 5 during pain assessment, 
whichever came first. Rescue analgesia consisted of 4 mg/kg of carprofen (Rimadyl
®
, Pfizer 
laboratories Lda – Animal Health Division, Guarulhos – São Paulo, Brazil) and 0,015 mg/kg 
of buprenorphine (Bupaq
®
, Richter Pharma AG, Wels, Austria). Fluidotherapy was done 
using sodium chloride 0,9% (Soro fisiológico BBRAUN Vet Care SA., Rubí, Spain) at a rate 
of approximately 5 mL/kg/h. The therapeutic protocol is summarized on table 4. 
Table 4 -Pharmacotherapeutical protocol. 
 Drug name Dose Route Obs. 
Pre-med Acepromazine + 
Methadone 
0,01-0,02 mg/kg + 
0,2 mg/kg 
IM Ace not given to patients 
<10kg. 15-30 min. prior to 
patient preparation. 
Induction Propofol 2 – 4 mg/kg IV To effect (allow intubation). 
Maintenance Isoflurane 1 – 4 %  - 
Rescue Carprofen + 
Buprenorphine 
4 mg/kg + 0,015 
mg/kg 
SC If pain score ≥ 5 or 6h post-
block. 
Antibiotherapy Amoxicilin + 
Clavulanic acid 
12,5 mg/kg SC - 
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3.4 Surgical technique 
An incision 2 to 4 cm long was done immediately caudal to the umbilical scar. Subcutaneous 
fat was debrided until the muscular layer was reached. Then, the linea alba was incised with a 
scalpel blade and the incision extended with the use of a Mayo scissors, while tenting the 
abdominal wall with the help of an Adson-Brawn forceps. Once the opening was satisfactory, 
the surgeon manually searched for the uterus, usually trying to find the right uterine horn first. 
Once found, the right ovary was lifted from its position and an haemostatic clamp was set 
between the ovary and the uterus horn, to secure the structure for ligature placement. A small 
hole in the broad ligament was done, to allow the passage of a suture in order to do the 
ligatures. Two ligatures were performed on the ovarian pedicle. Once tightly secured, two 
clamps were set between the ovary and the ligatures and the pedicle was incised in between 
them. The ligated pedicle was checked for hemorrhage and if it wasn’t present, slowly 
replaced in its place. Finally, the broad and round ligaments were ligated as well, before being 
incised. Then, following that uterine horn, the left uterine horn was found and the left ovary 
pulled up. The same procedure was repeated for this ovary. Once the left broad and round 
ligaments were incised, both horns were pulled caudally to expose the uterine body and 
cervix. The uterine body was ligated with a simple ligature first, followed by a transfixation 
ligature. Once that was accomplished, the uterine horn was clamped with two haemostatic 
clamps just cranial to the ligatures and the uterus incised in the middle of them. The uterine 
stump was checked for hemorrhage and if no hemorrhage was seen, the stump was replaced in 
its proper place and the pedicles’ ligatures re-checked for hemorrhages. If none were seen, the 
surgeon initiated the closure of the abdominal cavity. The peritoneum, the muscle layers and 
the muscle fascia were sutured together using a simple continuous pattern, reinforced with a 
simple interrupted pattern. Then an approximation suture was performed in the subcutaneous 
tissue and finally skin closure was achieved with an intradermic continuous pattern.  
3.5 Monitoring parameters 
Each patient had its own monitoring sheet, which comprised of all the data related to that 
patient, from physiological parameters to its behaviour. The individual doses for the 
pharmacotherapeutical protocol were registered, along with pre-medication, induction and 
other surgical procedure timings. Finally, it includes a table for pain assessment. This patient 
sheet can be seen in figure 5. 
35 
 
 
Figure 5 -  Monitoring sheet. (original photo) 
 
3.5.1 Physiological parameters 
From induction to the end of surgery, heart rate and respiratory rate were measured every 5 
minutes. It was not possible to measure blood pressure during the intervention due to the 
unreliability of the monitoring equipment and the lack of proper sized cuffs. Five time-points 
were set during surgery, corresponding to the most painful moments of surgical handling: skin 
incision (S1), clamping of first ovary (S2), clamping of second ovary (S3), ligature of the 
uterine body (S4) and beginning of closing sutures (S5). These were set in order to allow 
statistical analysis of these parameters.  
Patient nº Age
Patient name Weight
Species Temper
Breed
Ph. Examination: HR RR MM CRT TºC
Auscultation
Pulse rate/Quality
Blood work: HT TP Glu Urea ALAT
Venous cathether: pink blue yellow
Pre-oxigenation: min Sevoflurane %
Time Drug Route
Pre-med Acp               0.01 - 0.02 mg/kg mgTOT mlTOT
Methadone 0.2 mg/kg mgTOT mlTOT
Induction Propofol 2-4 mg/kg mgTOT mlTOT
Rescue Analgesia Carprofen 4 mg/kg mgTOT mlTOT
Buprenorphine 0.015 mg/kg mgTOT mlTOT
Nerve Blocks
Linea alba (Ropivacaine  2mg/kg mgTOT mlTOT)
Antibiotics Synulox 12.5 mg/kg mgTOT mlTOT
Emergency drugs Atropine 0.04 mg/kg mgTOT mlTOT
Dopamine 3-7 µg/kg/min ml/h
Fluid Therapy
Ringer 5-10 ml/kg/h ml/h
Ringer bolus 10 ml/kg mlTOT nº
Timings: Duration of procedure:
Incision Duration of anesthesia:
1st ovary Duration of monitoring:
2nd ovary Notes:
Uterine body
Closure
End of procedure
Extubation
Discharge
Pain assessment T1 T2 T3 T4 T5 T6 T7 T8
I
II
IV
V
VI
Total
Rescue
Notes:
Dose
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3.5.2 Pain scoring 
Pain assessment was initiated 30 minutes after extubation (T1) and continued every hour, up 
until 6 hours post-local block (T2 – T5). Only one observer scored the animals (the author) 
and the short form of the Glasgow’s Composite Measure Pain Scale (GCMPS) was used for 
this purpose, due to its ease of use for untrained people and because of its sensibility. The 
observer began the assessment by approaching the cage silently and watching the animal’s 
behaviour from afar for approximately one minute. Then, the observer opened the cage and 
greeted the patient, petting him on the head and over its back, observing the response (i.e. if 
the animal is awake, sedated, actively responding or just ignoring the stimuli). Then, with 
careful movements, the surgical site was palpated with two fingers gently pressing around and 
finally on the surgical incision, while recording carefully the patient’s reaction. Finally, the 
patient was left alone and watched from a distance to see if he stood awake or went to sleep 
again. Between T3 and T5, all patients were walked outside, after palpation of the wound site. 
3.6 Results analysis 
Differences between group age, weight, duration of procedure and of anesthesia were 
analyzed with a two-sample Wilcoxon test. Statistical differences in heart rate (HR), 
respiratory rate (RR) and pain scores (PS) between groups were calculated using a repeated 
measures ANOVA analysis. Minutes to HR and RR time-points were analyzed with 
descriptive statistical methods only. Statistical analysis was done with R v2.1.2. 
4. Results  
4.1 Study group 
From the 15 dogs that fulfilled the criteria, 14 were included in the study (see table 4). The 
one rejection was due to pregnancy, discovered during surgery (not included in table 4). Half 
of the patients didn’t belong to a specific breed. Breeds represented in the study are French 
Bulldog (x2), Yorkshire Terrier (x2), Boxer (x1), Husky (x1), and Jack Russel (x1). Breed 
influence was not analyzed. 
4.2 Age, weight, duration of procedure and of anesthesia  
Ages ranged from 8 months to 6 years and weights ranged from 2.7 kg to 31.3 kg. Average 
values for SG were: age = 1.63 ± 1.55 years, weight = 13.9 ± 7.0 kg, duration of surgery = 
38.7 ± 6 minutes and duration of anesthesia = 80.7 ± 13 minutes; and for RG were: age = 2.05 
± 1.93 years, weight = 11.4 ± 9.7 kg, duration of surgery = 37.7 ± 8 minutes and duration of 
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anesthesia = 71.1 ± 12 minutes. No signs of local anesthetic toxicity were seen during the 
study. Statistically, patients’ age, weight, duration of procedure and duration of anesthesia did 
not differ between groups (p = 0.743, p = 0.318, p = 0.796 and p = 0.337, respectively) (see 
Table 5). 
Table 5 - Descriptive statistics and statistical significance of age, weight, duration of procedure 
and of anestesia. 
Parameter SG RG P value 
Age (y) 1.63 ± 1.55 2.05 ± 1.93 0.743 
Weight (kg) 13.9 ± 7.0 11.4 ± 9.7 0.318 
Duration of procedure (min) 38.7 ± 6 37.7 ± 8 0.796 
Duration of anestesia (min) 80.7 ± 13 71.1 ± 12 0.337 
4.3 Heart and respiratory rate 
During surgery, the heart rate and breathing rate data was collected in the 5 time-points 
described in 3.5.1. Visually analyzing table 6, it is clear that those time points were very 
similar between groups, which mean the painful stimuli were inflicted roughly after a similar 
period of time had passed since administration of ropivacaine. Neither HR nor RR have 
statistically significant differences between groups (p = 0.990 and p = 0.529, respectively). 
There was a peak in both the monitorized parameters at S2 (see figure 6), coinciding with the 
pull on the first ovary pedicle, which might indicate that this is the most painful moment of 
the surgery and thus the anesthetist should be paying close attention to the patient at this time 
and act in order to prevent it as much as possible. Because HR and RR are extremely 
unreliable parameters for pain assessment when used individually, evaluation of anesthesia 
depth through the palpebral reflex was done simultaneously. Whenever possible, additional 
patient’s biological parameters should also be measured (i.e. blood pressure and pulse). 
Table 6 - Average time to time points. Average differences 
between groups were under 5 minutes. 
Time points 
Time to crucial time-points (min.) 
NaCl Ropi 
S1 21±5 17±7 
S2 24±5 21±6 
S3 31±4 28±5 
S4 37±5 33±6 
S5 44±6 39±6 
38 
 
 
Figure 6 - HR and RR over time. S1-S5 are the crucial time points. S0 is an average of the values 
between induction and incision. Bars represent a 95% confidence level. 
 
4.4 Rescue analgesia 
During the monitoring period, rescue analgesia was given to three dogs before ropivacaine’s 
effect had ended. However, none was due to a high pain score. Dog number 2 became very 
defensive during monitoring and wouldn’t allow the approach of the observer but was resting 
comfortably, ignoring the wound area and was happy and bouncy when he came out walking, 
dog number 4 was picked up by the owner sooner than expected and dog number 7 was 
mistakenly given the rescue analgesia before time. No dog exceeded the limit score that set 
the need for rescue analgesia (PS ≥ 5).  
4.5 Pain scores 
This study showed no differences in pain scores between groups (p = 0.638). It is interesting 
to see that by looking at the scores alone (Table 7), it might seem that patients that received 
ropivacaine infiltration have higher scores than the control patients. The reason for this trend 
is difficult to pinpoint, but some reasons might be: an unexpected reaction to ropivacaine 
(Does it sting or somehow bring some discomfort? Is the numbing sensation of a local 
anesthetic bothersome to some patients?), the result of a sub-optimal dose of local anesthetic 
(1 mg/kg was used instead of the usual 2 mg/kg from literature) or some other unknown 
reason. Since the sample size is small, the question remains if the same trend would remain if 
more patients were added to the study or if the recommended dose of ropivacaine was 
administered.  
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Table 7 - Pain scores of all the patients and respective groups. 
Group Patient 
nº 
T1 T2 T3 T4 T5 
NaCl 
1 2 0 0 0 0 
4 2 3 1 NA NA 
5 1 0 0 0 0 
7 3 2 4 NA NA 
8 1 0 0 0 0 
11 0 1 1 1 1 
13 3 4 3 2 2 
Ropi 
2 0 4 1 NA NA 
3 0 2 0 0 0 
6 2 4 1 1 1 
9 1 2 2 2 0 
10 2 1 3 3 3 
12 4 4 3 3 2 
14 0 0 0 0 0 
5. Discussion 
There are no studies on the use of ropivacaine in abdominal surgery in animals. However, in 
humans, it is proven to lower the need for post-operative analgesics, including the need for 
opioids, in women undergoing cesarean delivery (Bamigboye & Justus, 2008). Twenty-four 
women out of fifty of the ropivacaine group compared to forty-seven out of fifty of the 
control group, required pethidine or experienced severe pain during the first hour post-op. The 
use of other analgesics was also reduced in the ropivacaine group, compared to the control 
group (Bamigboye & Justus, 2008). The authors of that study administered ropivacaine 
directly into the surgical wound and sprayed in the peritoneum. In the present study, 
ropivacaine was administrated before surgical incision in a linear injection, subcutaneously 
over the area to be incised. The amount of ropivacaine also differed between studies: in this 
study, 1 mg/kg of ropivacaine was used, which is lower than the recommended dosage for 
local blocks, but was chosen due to volume issues with the 2 mg/kg dose (ropivacaine’s 
presentation was 0,5% or 5 mg/ml), since the surgical incision was very small (2 -4 cm); in 
the human study, 30ml of 0.75% ropivacaine (equivalent to 7,5 mg/ml) were used in every 
patient (Bamigboye & Justus, 2008). 
There are two studies that followed a similar approach, using lidocaine and bupivacaine 
instead and administering it in the wound incision and sprayed in the peritoneum (Carpenter, 
Wilson, & Evans, 2004; Campagnol, Teixeira-Neto, Monteiro, Restitutti, & Minto, 2012). 
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Their results were in favor of the use of intraperitoneal bupivacaine as a valid method of 
analgesia post-op in this surgery, with lower pain scores obtained in these groups, compared 
to control groups. Due to short supply of ropivacaine, it wasn’t possible to use it via intra-
peritoneum in the present study. Yet another study had a similar design to this one and the 
two mentioned above, but used only bupivacaine in a SC+IM administration technique and 
patients included weren’t limited to OVH procedures, but rather any celiotomy (Savvas, 
Papazoglou, Anagnostou, Tsioli, & Raptopoulos, 2008). 
This study failed to prove any advantage in the use of ropivacaine in the analgesic protocol of 
OVH in dogs. Due to the small differences between groups, the author concludes that in order 
to have statistical differences, the sample size should have been larger. Another similar study 
reached the same conclusion (Campagnol, Teixeira-Neto, Monteiro, Restitutti, & Minto, 
2012). Nonetheless, there is evidence that the SC use of a local anesthetic can be of benefit in 
these cases (Carpenter, Wilson, & Evans, 2004; Savvas, Papazoglou, Anagnostou, Tsioli, & 
Raptopoulos, 2008). In one of the studies the administration of local anesthetic was done SC 
before wound closure, along with IP spray (Carpenter, Wilson, & Evans, 2004) and in the 
other study the local anesthetic was given SC+IM (Savvas, Papazoglou, Anagnostou, Tsioli, 
& Raptopoulos, 2008). According to Savvas et al, there was evidence of effectiveness of this 
approach,  if the administration was done pre-incision rather than pre-wound closure. 
Due to the context of this study, there were some obstacles that might have contributed to the 
lack of observable differences. Since this study was set-up during the period of curricular 
training and in a public veterinary health establishment, its design had to be inserted in the 
routine of the hospital’s staff without causing much disturbance and it depended on the 
available resources for its realization. Thus, the author did not manage to gather the amount of 
patients originally pretended and the pre-surgical blood analysis couldn’t be too extensive, to 
avoid excessively charging the owners. Furthermore, the absence of a fully-fledged veterinary 
anesthetist limited the creation of a better adapted anesthetic protocol to the study’s objectives 
by restraining the drug selection to those the in-house surgeon felt comfortable using. Finally, 
ropivacaine’s availability in Portugal is quite limited, both in quantity and in presentation, fact 
that ended with the author using a presentation that had a sub-optimal concentration, which 
led to the change in the ropivacaine’s dose in the protocol. 
Despite the lack of results, the author still believes that they could’ve been obtained if the 
study was designed with slight adjustments, noticed and learned throughout the study period. 
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Patient selection should be tighter, taking into account animal behaviour, in order to prevent 
too fearful or too aggressive animals to be included in the study. These attitudes highly hinder 
pain assessment and might induce the observer into scoring a patient wrongly. It should also 
be useful to not include pediatric and geriatric patients in the same study, as both groups of 
patients have slight differences in pain perception (interference of dessensitization 
phenomenon or presence of chronic pain originated from geriatric health problems). Blood 
pressure should be monitored during surgery, as it grants one more parameter for nociception 
assessment during the procedure. The surgery protocol could be revised, giving preference to 
short-duration analgesia for the intra-operative period and a higher dose of local anesthetic, 
normalized to a 0.75% concentration, to assure a good spread of the anesthetic. This would 
assure that in the post-op period analgesia would be provided solely by the local anesthetic 
and that it was administered in a proper dose. Finally, the administration technique should be 
changed into SC+IM administration, as it has proven to be a reliable technique (Savvas, 
Papazoglou, Anagnostou, Tsioli, & Raptopoulos, 2008).  
In conclusion, anesthesia with methadone, acepromazine, propofol and isoflurane provided 
reliable analgesia during and after the procedure, since no supplemental analgesics were 
needed in the control group. The pre-incisional administration of 1 mg/kg SC of ropivacaine 
did not show any effectiveness in lowering post-operative pain scores.  
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